Genome-wide association study identifies a role for the progesterone receptor in benign prostatic hyperplasia risk.

Benign prostatic hyperplasia (BPH) is common noncancerous prostate enlargement, which is usually associated with lower urinary tract symptoms (LUTS) and can lead to complex urinary, bladder, or kidney diseases.